(Total Views: 510)
Posted On: 10/07/2020 10:46:15 AM
Post# of 148908
Re: Rubraquercus #60145
The data from CD10 was sufficient for EUA. The question after that is if fda has any interest in approval for mild/moderate.
It seems that communicate from fda in that indication remains unclear, with interest in antivirals and vaccines, with therapy desired by them only for severe.
It is a bit of a reach imo to hold NP accountable for the shifting fda expectations.
This is one area where I believe his communication was as timely as expected as Cytodyn was not given any concrete direction from fda in m/m.
It seems that communicate from fda in that indication remains unclear, with interest in antivirals and vaccines, with therapy desired by them only for severe.
It is a bit of a reach imo to hold NP accountable for the shifting fda expectations.
This is one area where I believe his communication was as timely as expected as Cytodyn was not given any concrete direction from fda in m/m.
(4)
(2)Scroll down for more posts ▼
